Telix Pharmaceuticals
The CMC Program Lead will drive the commercial readiness and lifecycle management of radiopharmaceutical assets, including Illuccix and Gozellix, by executing CMC strategies across API, Fill/Finish, and Secondary Packaging partners. This role involves coordinating cross-functional teams, managing vendor relationships, and ensuring regulatory compliance for ongoing commercial viability and market expansion. The position requires leading project dashboards, budgets, and risk mitigation strategies while facilitating smooth transitions from development to commercial phases.
Headquarters
North Melbourne, Victoria, Australia
Company Size
201-500 employees
Founded
2015
Telix Pharmaceuticals is a global, commercial‑stage biopharmaceutical company developing diagnostic and therapeutic “theranostic” products that use targeted radiation to detect and treat cancer. It advances radiopharmaceuticals through clinical development, regulatory approval, manufacturing and commercialisation to bring imaging agents and targeted therapies to patients. Telix works with the nuclear medicine community and international partners to scale access and improve outcomes. Its stated mission is to help patients with cancer live longer with better quality lives.
TLX DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Dec 14, 2025
Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX
Nov 13, 2025
Pharma groups rush to calm investor fears over Trump’s tariff hit
Sep 26, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Telix Pharmaceuticals.
The Market Doesn't Like What It Sees From Telix Pharmaceuticals Limited's (ASX:TLX) Revenues Yet As Shares Tumble 26%
Dec 31, 2025